Latest / Community Health Media
Dr. Irene Kang & Dr. Aditya Bardia - First-Line HER2+ Metastatic Breast Cancer: DESTINY-Breast09 & the Future of Care
Recorded live, this in-depth conversation features Dr. Irene Kang and Dr. Aditya Bardia breaking down the DESTINY-Breast09 data and what it means for first-line treatment of metastatic HER2-positive breast cancer.
From challenging the long-standing THP standard to unpacking unprecedented progression-free survival, higher complete response rates, and CNS activity with T-DXd, this discussion explores how and why first-line decision-making is evolving. The panel also dives into patient selection, toxicity management, ILD monitoring, dose optimization, induction vs maintenance strategies, and how…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.